Business Description
Hansa Biopharma AB
SIC : 2834
ISIN : SE0002148817
Share Class Description:
MEX:HNSA: Ordinary SharesCompare
Compare
Traded in other countries / regions
HNSA.Sweden0RC7.UK24H.GermanyHNSA.MexicoHNSBF.USA IPO Date
2019-06-14Description
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.57 | |||||
| Equity-to-Asset | -0.45 | |||||
| Debt-to-Equity | -2.53 | |||||
| Debt-to-EBITDA | -1.36 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -0.37 | |||||
| Beneish M-Score | -2.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 160.1 | |||||
| 3-Year EBITDA Growth Rate | -11.1 | |||||
| 3-Year EPS without NRI Growth Rate | -16.5 | |||||
| 3-Year FCF Growth Rate | -27.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.58 | |||||
| Future 3-5Y Total Revenue Growth Rate | 59.44 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.55 | |||||
| Quick Ratio | 2.55 | |||||
| Cash Ratio | 2.1 | |||||
| Days Inventory | 9.55 | |||||
| Days Sales Outstanding | 146.17 | |||||
| Days Payable | 380.62 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.8 | |||||
| Shareholder Yield % | -8.73 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 56.8 | |||||
| Operating Margin % | -463.1 | |||||
| Net Margin % | -509.33 | |||||
| FCF Margin % | -441.18 | |||||
| ROA % | -71.82 | |||||
| ROIC % | -188.35 | |||||
| ROC (Joel Greenblatt) % | -2376.08 | |||||
| ROCE % | -78.09 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 15.72 | |||||
| EV-to-EBIT | -5.24 | |||||
| EV-to-EBITDA | -5.24 | |||||
| EV-to-Revenue | 21.99 | |||||
| EV-to-FCF | -5.1 | |||||
| Price-to-Median-PS-Value | 0.03 | |||||
| Earnings Yield (Greenblatt) % | -19.09 | |||||
| FCF Yield % | -22.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hansa Biopharma AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 268.995 | ||
| EPS (TTM) (MXN) | -25.738 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0 | ||
| 20-Day SMA (MXN) | 160.75 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 160.75 - 160.75 | ||
| Shares Outstanding (Mil) | 67.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hansa Biopharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hansa Biopharma AB Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hansa Biopharma AB Frequently Asked Questions
What is Hansa Biopharma AB(MEX:HNSA)'s stock price today?
The current price of MEX:HNSA is MXN160.75. The 52 week high of MEX:HNSA is MXN160.75 and 52 week low is MXN160.75.
When is next earnings date of Hansa Biopharma AB(MEX:HNSA)?
The next earnings date of Hansa Biopharma AB(MEX:HNSA) is 2024-07-18.
Does Hansa Biopharma AB(MEX:HNSA) pay dividends? If so, how much?
Hansa Biopharma AB(MEX:HNSA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers